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the Urinary excretion of 
Uromodulin is Regulated by the 
potassium channel RoMK
Guglielmo Schiano1,4, Bob Glaudemans1,4, Eric olinger1, Nadine Goelz1, Michael Müller2, 
Dominique Loffing-cueni2, Georges Deschenes  3, Johannes Loffing2 & olivier Devuyst  1*
Uromodulin, the most abundant protein in normal urine, is produced by cells lining the thick ascending 
limb (TAL) of the loop of Henle. Uromodulin regulates the activity of the potassium channel ROMK in 
TAL cells. Common variants in KCNJ1, the gene encoding ROMK, are associated with urinary levels 
of uromodulin in population studies. Here, we investigated the functional link between ROMK and 
uromodulin in Kcnj1 knock-out mouse models, in primary cultures of mouse TAL (mTAL) cells, and in 
patients with Bartter syndrome due to KCNJ1 mutations. Both global and kidney-specific Kcnj1 knock-
out mice showed reduced urinary levels of uromodulin paralleled by increased levels in the kidney, 
compared to wild-type controls. Pharmacological inhibition and genetic deletion of ROMK in mTAL 
cells caused a reduction in apical uromodulin excretion, reflected by cellular accumulation. In contrast, 
NKCC2 inhibition showed no effect on uromodulin processing. Patients with Bartter syndrome type 
2 showed reduced urinary uromodulin levels compared to age and gender matched controls. These 
results demonstrate that ROMK directly regulates processing and release of uromodulin by TAL cells, 
independently from NKCC2. They support the functional link between transport activity and uromodulin 
in the TAL, relevant for blood pressure control and urinary concentrating ability.
Uromodulin (previously named Tamm-Horsfall protein) is the most abundant protein excreted in normal human 
urine. This extracellular matrix-type protein is essentially produced and excreted in the urine by the epithelial 
cells lining the thick ascending limb (TAL) of Henle’s loop1. A sizeable expression of uromodulin, approximately 
10% of the level observed in the TAL, is also detected in the early part of the distal convoluted tubule (DCT)2. 
Important roles for uromodulin include protection against urinary tract infections by binding to type 1 – fimbri-
ated uropathogenic E. coli3,4; reduction of kidney stone formation by binding calcium oxalate crystals5,6; and reg-
ulation of the Na+-cotransporters NKCC2 (SLC12A1) and NCC (SLC12A3) in the apical membrane of the TAL 
and DCT cells, respectively2,7,8. The functional importance of uromodulin is also supported by genetic evidence. 
Genome-wide association studies (GWAS) have shown that common variants in the promoter of the UMOD gene 
that encodes uromodulin are associated with estimated glomerular filtration rate (eGFR) and the risk of chronic 
kidney disease (CKD) and hypertension in the general population9–11. Furthermore, rare mutations in UMOD 
are causing autosomal dominant tubulointerstitial kidney disease (ADTKD-UMOD), a gain of toxic function 
disorder due to abnormal accumulation of mutant uromodulin aggregates in the TAL, leading to kidney fibrosis 
and CKD12,13.
In contrast with its roles in the kidney, the regulation of uromodulin production and release in the urine 
remains poorly characterized. Uromodulin is a glycosylphosphatidyl-inositol (GPI)-anchored protein that is tar-
geted to the apical membrane of tubular cells, where it is subsequently cleaved and released in the lumen by the 
serine protease hepsin14. Once cleaved and released in the lumen, the uromodulin monomers assemble via their 
Zona Pellucida (ZP) domain to form a dense matrix of high-molecular weight polymers constituting hyaline 
casts1. Based on a meta-GWAS of urinary uromodulin level in the general population, a candidate gene analysis 
revealed that the gene with the strongest association with urinary uromodulin was KCNJ1 coding for the apical 
K+ channel ROMK15.
ROMK co-localizes with uromodulin at the apical membrane of TAL cells, where it recycles part of the 
reabsorbed K+ from the intracellular compartment back to the tubular lumen – a process that is essential for 
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maintaining the activity of NKCC216,17. Inactivating mutations of KCNJ1 cause antenatal Bartter syndrome 
type 2, a rare disorder characterized by salt wasting, hypokalemic metabolic alkalosis, hypercalciuria, and 
secondary nephrocalcinosis18. Renigunta et al. identified uromodulin as an interaction partner of ROMK 
in yeast-two-hybrid screens, with transport activity and surface expression of ROMK being increased when 
co-expressed with uromodulin in Xenopus laevis oocytes19. Furthermore, Umod−/− mice showed defective apical 
targeting of ROMK, reflecting accumulation of the channel in intracellular vesicles19.
The genetic and functional data summarized above suggest a complex interplay between ROMK and uro-
modulin, which could be relevant in vivo – as modifications in TAL function increasingly appear to influence the 
release of uromodulin in urine20–22. In the present study, we used various Kcnj1 knock-out (KO) mouse models, 
differentiated primary cell cultures obtained from mouse TAL and urine samples from individuals harbouring 
inactivating mutations of KCNJ1 to investigate the effect of ROMK deficiency on uromodulin expression, pro-
cessing and release in the urine.
Results
Uromodulin expression and processing in Kcnj1 knock-out mice. The interplay between ROMK 
and uromodulin was first investigated in the constitutive, global Kcnj1 KO compared to control littermates. Only 
male Kcnj1−/− mice were included in this study due to their less severe phenotype and higher survival rate23. 
Histological examination of the Kcnj1−/− kidneys evidenced hydronephrosis and severe thinning of the medulla 
(Fig. 1a). At the mRNA level (Fig. 1b), global ROMK deficiency was reflected by a slight downregulation of uro-
modulin expression (Umod: 83 ± 2% of control; P < 0.05) in Kcnj1−/− compared to Kcnj1+/+ kidneys, whereas 
other TAL genes were either significantly decreased (Slc12a1: 54 ± 3% of control; P < 0.0001) or increased 
(Clcnkb: 163 ± 6% of control; P < 0.0001; Cldn16: 187 ± 7% of control; P < 0.0001). Of note, ROMK deletion was 
reflected by a significant upregulation of genes expressed in the DCT, including Slc12a3 (292 ± 37% of control; 
P < 0.001) and Pvalb (349 ± 63% of control; P < 0.01) and in the connecting tubule/collecting duct (CNT/CD) 
segments, including Aqp2 (154 ± 13% of control; P < 0.01), Scnn1b (150 ± 7% of control; P < 0.001) and Scnn1g 
(170 ± 4% of control; P < 0.0001), whereas the expression of proximal tubule (PT) genes Sglt2 (59 ± 4% of control; 
P < 0.01) and Aqp1 (64 ± 3% of control; P < 0.05) was significantly decreased in Kcnj1−/− mice (Fig. 1b).
Immunoblotting analyses confirmed that NKCC2 protein levels were significantly lowered in total kidney 
lysates from Kcnj1−/− mice (60 ± 5% of control; n = 5; P < 0.001), strongly contrasting with total kidney uromod-
ulin levels, which were significantly higher (300 ± 29% of control; n = 5; P < 0.001) in Kcnj1−/− kidneys (Fig. 1c). 
To identify the cellular localization of the increased uromodulin signal, we separated membrane and cytosolic 
fractions obtained from the kidneys of Kcnj1−/− and Kcnj1+/+ mice. The purity of these fractions was assessed 
by probing with anti-GAPDH (membrane) and anti-flotillin-1 (cytosolic). Compared to Kcnj1+/+ kidneys, we 
detected an increase in uromodulin both in the membrane (232 ± 24% of control, n = 5; P < 0.01; Fig. 1d) and 
cytosolic (1389 ± 433% of control, n = 5; P = 0.003; Fig. 1e) fractions from Kcnj1−/− kidneys.
The modifications of uromodulin expression were further analysed using confocal microscopy on sections of 
Kcnj1 mouse kidneys (Fig. 1f). Although uromodulin showed a similar localization at or close to the apical mem-
brane of TAL cells (sub-apical vesicles) in both genotypes, the signal was more intense in the Kcnj1−/− compared 
to Kcnj1+/+ kidneys. Of note, the apical staining of NKCC2 was also stronger in Kcnj1−/− kidneys, despite the 
global reduction of NKCC2 expression, suggesting an overall reduction in TAL mass.
Metabolic studies indicated that Kcnj1−/− mice presented similar body weight, BUN and creatinine clearance 
levels than Kcnj1+/+ littermates, despite polyuria with diluted urine (Table 1). The plasma Na+ and Cl- concentra-
tions were similar between Kcnj1−/− and Kcnj1+/+ mice, except for a mild decrease in plasma K+ concentration 
in Kcnj1−/− animals.
Immunoblotting experiments showed a ~60% reduction of urinary uromodulin levels (normalized for urinary 
creatinine levels to account for differences in urine concentration), in Kcnj1−/− mice compared to control mice 
(41 ± 11%, n = 6; p < 0.001) (Fig. 2a). The decreased urinary excretion was confirmed by ELISA (51 ± 4.0 µg/
mg creat. vs 102 ± 12 µg/mg creat. in Kcnj1+/+, n = 10/11, P < 0.001) (Fig. 2b). Urinary uromodulin excreted in 
Kcnj1−/− mice retained similar N-glycosylation pattern compared to wild-type as PNGase F treatment led to a 
~30 kDa shift compared to untreated samples (Fig. 2c).
These data indicate that the constitutive deletion of ROMK is reflected by an apical and cytosolic accumulation 
of uromodulin in the TAL cells, paralleled by a lower urine excretion of the protein.
processing and excretion of uromodulin in Kcnj1fl/flPax8Cre/+ mice. To confirm that the cellular accu-
mulation and reduced urinary excretion of uromodulin is a direct consequence of Kcnj1 deletion, and not secondary 
to systemic effects of chronic/global ROMK deletion (constitutive KO), we investigated uromodulin processing in 
an inducible, kidney-specific Kcnj1 KO mouse model. This line uses the mouse Pax8 promoter to drive the expres-
sion of a reverse tetracycline-dependent transactivator to obtain an inducible Cre expression in all kidney tubule 
segments24. The Pax8rtTA/LC-1 mice were crossed to transgenic mice harbouring floxed Kcnj1 (Penton et al., 
MS under revision) allowing to delete Kcnj1 after treatment with doxycycline. Compared to Kcnj1fl/flPax8+/+  
littermates, Kcnj1fl/flPax8Cre/+ mice showed a significant reduction in urinary uromodulin (75 ± 3%, n = 4, 
P < 0.001), and a concomitant accumulation of uromodulin in the kidney (216 ± 47%, n = 4, P < 0.01) (Fig. 3a) 
where it is located at the apical pole of the TAL cells (Fig. 3b). These data confirm the direct link between ROMK 
and uromodulin excretion and processing in the TAL.
ROMK inhibition in primary mouse TAL cells affects uromodulin processing. We next used 
a well-established system of primary mTAL cells obtained from TAL segments isolated from mouse kidneys, 
in order to directly assess the effect of apical transport systems on endogenous uromodulin processing. The 
mTAL cells cultured on permeable filters express NKCC2 and ROMK at the apical membrane and generate a 
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lumen-positive transepithelial potential that is abolished by apical bumetanide. Critically, the mTAL cells express 
endogenous uromodulin, which is processed and secreted in the apical medium similar to the situation observed 
in vivo25. Differentiated monolayers of mTAL cells were exposed to non-toxic concentrations of bumetanide (a 
specific inhibitor of NKCC2) and BaCl2 (a blocker of K+ channels). Exposure of the apical side of primary TAL 
Figure 1. Histological characterization, transcript analysis and uromodulin processing in Kcnj1−/− mice. 
(a) Haematoxylin and eosin (H&E) staining of 12 weeks Kcnj1+/+ and Kcnj1−/− kidneys. Scale bars: low 
magnification - 2 mm, high magnification - 100 μm (b) Quantitative PCR analysis of tubular marker genes 
in Kcnj1−/− kidneys. Glom (Glomerulus): Nphs2 (Podocin); PT (Proximal Tubule): Slc5a2 - Sodium/glucose 
cotransporter 2 (SGLT2), Aqp1 - Aquaporin 1; TAL (Thick Ascending Limb): Slc12a1 - Na/K/Cl cotransporter 2 
(NKCC2), Umod - Uromodulin; DCT (Distal Convoluted Tubule): Slc12a3 - Na/Cl cotransporter (NCC), Pvalb - 
Parvalbumin; CNT/CD (Connecting Tubule/Collecting Duct): Aqp2 - Aquaporin 2, Scnn1b - Sodium channel 
epithelial 1 beta subunit (β-ENaC), Scnn1g - Sodium channel epithelial 1 gamma subunit (γ-ENaC); Cldn16 -  
Claudin 16 and Clcnkb (Cl channel Kb) are localized in both TAL and DCT. (c) Representative Western blot 
analysis on whole kidney lysates of 12 weeks Kcnj1+/+ and Kcnj1−/− mice. β-actin was used as a loading control. 
(d) Representative Western blot analysis on kidney membrane fractions of 12 weeks Kcnj1+/+ and Kcnj1−/− 
mice. Flotillin-1 was used as a loading control, whereas GAPDH was used to test cytosolic contamination. (e) 
Representative Western blot analysis on kidney cytosolic fractions of 12 weeks Kcnj1+/+ and Kcnj1−/− mice. 
GAPDH was used as a loading control, whereas Flotillin-1 was used to test membrane contamination. (f) 
Immunofluorescence analysis for UMOD (green) and NKCC2 (red) in Kcnj1+/+ and Kcnj1−/− serial kidney 
sections. Scale bars: low magnification - 50 μm, high magnification - 15 μm. Full length blot images can be 
found in Supplementary Figure S2.
4Scientific RepoRtS |         (2019) 9:19517  | https://doi.org/10.1038/s41598-019-55771-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
monolayers to bumetanide (100 µM) or BaCl2 (5 mM) resulted in a robust and sustained inhibition of Vte (Suppl. 
Fig. S1a). Measurement of transepithelial resistance (Rte) of mTAL monolayers after 12 h exposure to bumetanide 
(349 ± 11 Ω/0.33 cm2, n = 7, P < 0.05) and BaCl2 (389 ± 8 Ω/0.33 cm2, n = 7, P < 0.001) revealed a significant 
increase in Rte compared to 0.1% EtOH vehicle (311 ± 11 Ω/0.33 cm2, n = 8), indicating an effective blocking of 
the transport (Fig. 4a). Uromodulin levels in the apical medium were first measured after a 12 h input in order to 
assess baseline uromodulin excretion rates, and then after 12 h exposure to apical BaCl2, bumetanide or in control 
conditions. Compared to baseline levels, a strong decrease of apical uromodulin excretion was observed in the 
presence of apical BaCl2 (BaCl2: 63 ± 11% of input, n = 8, P < 0.01) but not with bumetanide (100 ± 19%, n = 8) or 
0.1% EtOH vehicle (142 ± 18% of input, n = 8). In parallel, the level of cellular uromodulin was largely increased 
Kcnj1+/+ Kcnj1−/− N
Body weight (g) 28.5 ± 0.7 28.5 ± 0.9 11/11
Urine volume (µL/16 h) 977 ± 134 2829 ± 440*** 11/11
Plasma Creatinine (µmol/L) 20 ± 1 27 ± 2 6/6
Blood urea nitrogen (mg/dL) 28 ± 1 31 ± 3 6/6
Plasma [Na+](mmol/L) 154 ± 1 153 ± 1 6/6
Plasma [K+] (mmol/L) 5.7 ± 0.2 4.9 ± 0.3* 6/6
Plasma [Cl−] (mmol/L) 109 ± 0 106 ± 1 6/6
Plasma [Ca2+] (mmol/L) 2.59 ± 0.02 2.70 ± 0.05 6/6
Urinary Creatinine (mg/dL) 51.4 ± 4.9 14.9 ± 1.2*** 11/11
Urinary osmolality (mOsm/kgH2O) 1780 ± 108 645 ± 24*** 11/11
Na+ excretion (µmol/16 h) 110 ± 16 87 ± 15 11/11
K+ excretion (µmol/16 h) 200 ± 35 185 ± 25 11/11
Cl− excretion (µmol/16 h) 143 ± 28 120 ± 20 11/11
Ca2+ excretion (µmol/16 h) 1.01 ± 0.25 1.98 ± 0.74 11/5
CCr (mL/min) 0.16 ± 0.04 0.14 ± 0.01 6/6
Table 1. Physiological and biochemical parameters in Kcnj1 mice. Values are presented as average ± SEM. 
*P ≤ 0.05, ***P ≤ 0.001 Kcnj1+/+ versus Kcnj1−/− mice. n: number of animals; CCr: Creatinine clearance.
Figure 2. Kcnj1−/− mice show reduced urinary uromodulin. (a) Representative Western blot of urinary 
uromodulin (UMOD) in 12 weeks Kcnj1+/+ and Kcnj1−/− mice. Urinary creatinine was used as a loading 
control. (b) Enzyme-linked immunosorbent assay (ELISA) of urinary uromodulin in 12 weeks Kcnj1+/+ 
and Kcnj1−/− mice. Uromodulin concentration was normalized on urinary creatinine. (c) Western blot for 
uromodulin (UMOD) in control and deglycosylated (PNGase F treatment) urine samples from Kcnj1+/+ and 
Kcnj1−/− mice. Samples were denatured by heating and treated according to the manufacturer’s instructions. 
Full length blot images can be found in Supplementary Figure S2.
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after BaCl2 exposure (305 ± 37% of control, n = 8, P < 0.001), whereas it remained unchanged after exposure to 
bumetanide (116 ± 27% of control, n = 8, P = 0.83) (Fig. 4b).
Since BaCl2 is a nonspecific K+ channel blocker, we exposed mTAL cells to VU591, a selective inhibitor of 
ROMK that is totally effective at 30 μM in rats26. Apical Treatment with VU591 led to a transient decrease in Vte 
(Suppl. Fig. S1b) and a dosage-dependent increase in Rte (0.1% DMSO vehicle: 295 ± 19 Ω/0.33 cm2, n = 4; 30 μM 
VU591: 707 ± 44 Ω/0.33 cm2, n = 4, P < 0.001; 60 μM VU591: 957 ± 19 Ω/0.33 cm2, n = 4, P < 0.001) (Fig. 4c). 
This treatment led to a dosage-dependent reduction in the 12 h input-paired excretion of uromodulin to the api-
cal side (0.1% DMSO vehicle: 82 ± 17%, n = 4; 30 μM VU591: 72 ± 8%, n = 4, P > 0.05; 60 μM VU591: 55 ± 7%, 
n = 4, P < 0.05) and at the 60 μM dose, an increase of cellular uromodulin (186 ± 15%, n = 3, P < 0.01) (Fig. 4d). 
These changes occurred in absence of any significant effect on cell viability (MTT assay: 95 ± 13% of vehicle, 
n = 3).
Kcnj1 deletion in mTAL cells leads to reduced uromodulin excretion. We next used mTAL cells to 
directly test the effect of deleting ROMK on uromodulin processing. To that end, we deleted ROMK in mTAL cells 
obtained from Kcnj1fl/fl mice and transfected with an adenoviral vector expressing either Cre recombinase fused 
with GFP (AdenoCre) or GFP alone (Mock)27. As expected, transfection of mTAL cells with AdenoCre resulted 
in a specific >90% decrease of ROMK protein expression (10 ± 4%, n = 4, P < 0.001) (Fig. 5a), that was reflected 
by a strong decrease in transepithelial lumen-positive Vte and an increase in Rte (Fig. 5c). The deletion of ROMK 
induced a 70% decrease in the apical excretion of uromodulin (28.5 ± 3.4% compared to mock, n = 4, P < 0.001) 
that was paralleled by a significant cellular accumulation as assessed by Western blotting on cell lysate (123 ± 6% 
compared to mock, n = 4, P < 0.05) and immunofluorescent staining on mTAL monolayers (Fig. 5b,d). These 
data confirm the cell-autonomous link between ROMK activity, transepithelial resistance/voltage and handling 
of uromodulin in TAL cells.
Uromodulin excretion is decreased in Bartter-type 2 patients. The translational relevance of the link 
between ROMK function and uromodulin excretion was tested in a cohort of patients with antenatal Bartter syn-
drome type 2 due to KCNJ1 mutations (Fig. 6a; Suppl. Table S1). When compared to the distribution of urinary 
uromodulin concentrations (as assessed by ELISA28 and normalized to creatinine) in a GFR-matched healthy 
reference population (n = 82), uromodulin concentration was below the 25th percentile of the reference popu-
lation in 5/7 patients. In contrast, age and gender-matched control individuals from the same families (n = 10) 
Figure 3. Kcnj1fl/flPax8Cre/+ mice show reduced urinary uromodulin with accumulation in the kidney. (a) 
Representative Western blot analysis for uromodulin (UMOD) and ROMK in urine and whole kidney lysates 
of Kcnj1fl/flPax8+/+and Kcnj1fl/flPax8Cre/+ mice after doxycycline induction. β-actin was used as a loading control. 
(b) Immunofluorescence staining for uromodulin of Kcnj1fl/flPax8+/+ and Kcnj1fl/flPax8Cre/+ kidney cryosections 
(scale bar: 50 µm). Full length blot images can be found in Supplementary Figure S2.
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had urinary uromodulin levels comparable to the reference population. The urinary uromodulin level was signif-
icantly lower in Bartter type 2 patients when compared to related control individuals (13.1 ± 5.0 vs. 26.2 ± 5.1 µg/
mg creat, respectively, P < 0.05) and to the reference population (27.6 ± 1.8 µg/mg creat, P < 0.05) (Fig. 6b; Suppl. 
Table S2). Western blot analysis of urine samples also showed a ~70% reduction in the level of uromodulin nor-
malized to creatinine in Bartter 2 patients compared to the related controls (36 ± 13%, n = 4, P < 0.01) with no 
apparent shift in molecular weight in control and deglycosylated conditions (Fig. 6c).
Discussion
Despite the identification of important roles of uromodulin in physiology and disease over the last decade, the 
regulatory mechanisms involved in its production, processing and release into the urine remain poorly charac-
terized. Based on evidence obtained from cellular studies, mouse models and human samples, we establish for 
the first time a link between the function of the K+ channel ROMK and the urinary excretion of uromodulin. We 
show that constitutive or induced genetic deletion of ROMK or its pharmacologic blockage result in defective 
apical excretion of uromodulin. The levels of uromodulin in urine are also significantly decreased in patients 
harbouring loss-of-function mutations in KCNJ1 responsible for Bartter syndrome type 2, compared to levels 
observed in age-matched controls from the same family or from a reference population.
Uromodulin is an abundant protein essentially produced in the epithelial cells lining the TAL, where it is 
apically targeted and released in the urine following proteolytic cleavage1. The TAL cells play a major role in the 
reabsorption of NaCl and divalent cations, and in the generation of the osmotic gradient allowing to concen-
trate urine. The transport processes operating in the TAL are somehow linked, as evidenced by the phenotype 
overlap observed in the various types of Bartter syndrome29. In fact, early studies suggested that the levels of uro-
modulin excretion may be lower in at least some patients with clinically diagnosed (but not genetically proven) 
Bartter syndrome30,31. The hypothesis of a link between uromodulin excretion and ROMK was substantiated 
by a meta-GWAS followed by a candidate gene approach for urinary uromodulin level in 10,884 individuals of 
European ancestry15. Among 24 candidate genes expressed and known to be involved in transport processes 
in the TAL, the most significant SNP associated with the urinary level of uromodulin was identified in KCNJ1 
coding for ROMK15. Also, uromodulin levels were shown to correlate with tubular handling of electrolytes in 
population-based studies21,22.
We provide multi-level evidence supporting a direct link between the expression and activity of ROMK and 
the processing and excretion of uromodulin by TAL cells. In vivo studies in constitutive and inducible Kcnj1 KO 
Figure 4. Effects of pharmacological ROMK inhibition on uromodulin processing. (a) Transepithelial 
resistance (Rte) of primary cultures obtained from microdissected TALs (mTAL) of wild-type mice after 12 hours 
treatment with 100 µM bumetanide (NKCC2 blocker) or 5 mM BaCl2 (K+ channels blocker). (b) Representative 
Western blot of secreted and cellular uromodulin (UMOD) in mTAL cells. Apical medium was collected 
12 hours before and after treatment with bumetanide or BaCl2 (as in panel a). (c) Transepithelial resistance 
(Rte) of mTAL cells 20 minutes after treatment with either 30 µM or 60 µM VU591 (ROMK inhibitor). (d) 
Representative Western blot of secreted and cellular uromodulin in mTAL cells. Apical medium was collected 
12 hours before and after treatment with VU591. Full length blot images can be found in Supplementary 
Figure S2.
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mouse models demonstrate that deletion of ROMK leads to a marked defect in uromodulin processing in the 
TAL, as indicated by intracellular accumulation and lower urine excretion. The similar effects observed in the two 
models indicate that the influence of ROMK on uromodulin processing is independent of any long-term effect 
secondary to its deletion. We substantiated the link between ROMK and uromodulin using mTAL cells, which 
endogenously express uromodulin25. Pharmacologic blockade of ROMK using non-selective BaCl2 or selective 
VU591, which led to the expected increase of transepithelial resistance (Rte), was associated with a marked cellu-
lar accumulation and a decrease in the apical excretion of uromodulin. The effect was specifically due to ROMK, 
since NKCC2 inhibition by bumetanide did not significantly reduce uromodulin excretion.
Because uromodulin excretion was significantly reduced after pharmacological inhibition and genetic dele-
tion of ROMK and in patients harbouring KCNJ1 mutations, we can assume that ROMK channel function and 
not the protein expression per se modulates uromodulin excretion. Inwardly rectifying potassium (Kir) channels 
are important regulators of resting membrane potential and ROMK is critical for maintaining the lumen-positive 
transepithelial voltage in the TAL32. In some cell types, membrane potential has been shown to modulate the 
trafficking of membrane proteins33. It would be interesting to test whether such membrane potential-dependent 
trafficking mechanism could contribute to the observed alterations in uromodulin excretion. Due to its abundant 
sugar moieties, uromodulin presents as a negatively charged protein at physiological pH and is associated with 
lipid rafts1. Lipid rafts themselves are rich in gangliosides and negatively charged and have been shown to act as 
electric field sensors and to polarize when exposed to an electric current34. The physiological TAL lumen-positive 
voltage might thus contribute to a preferential apical raft (and uromodulin) distribution that is disrupted in 
ROMK deficient cells.
The Bartter type 2 patients investigated here were taking numerous medications at time of sampling, including 
NaCl and KCl supplements, calcium and vitamin D, and indomethacin. The potential effect of these medications 
(individual or in combination) on the processing and urinary levels of uromodulin has not been systematically 
tested. It should also be pointed that the defect in uromodulin processing might contribute to the Bartter syn-
drome phenotype. The expression of uromodulin modulates the activity of NKCC2 and ROMK in the TAL7,19, 
and its deletion in mouse leads to a discrete salt-losing phenotype35. We recently showed that defective processing 
Figure 5. AdenoCre-mediated deletion of Kcnj1 in primary mouse TAL cells. (a) Representative Western 
blot analysis for NKCC2 and ROMK in primary cultured (mTAL) cells obtained from microdissected TAL 
segments of Kcnj1fl/fl kidneys. Cells were transduced with either an empty adenoviral vector (Mock) or an 
individual expressing Cre-recombinase (Adeno-Cre). β-actin was used as a loading control. (b) Representative 
Western blot analysis of secreted and cellular uromodulin (UMOD) from Kcnj1fl/fl mTAL cells treated with 
Mock or Adeno-Cre. (c) Transepithelial resistance (Rte) of Kcnj1fl/fl mTAL cells 5 days after Mock or Adeno-
Cre transduction. (d) Immunofluorescence for uromodulin in Kcnj1fl/fl mTAL cells after Mock or Adeno-Cre 
transduction. Full length blot images can be found in Supplementary Figure S2.
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of uromodulin (due to hepsin mutation) is causing TAL dysfunction and salt wasting36. All these effects could 
contribute to the tubular dysfunction typically observed in patients with Bartter syndrome.
Altogether, our data demonstrate that deficient ROMK function affects the processing and urinary excretion 
of uromodulin, supporting the mutual dependence of critical processes taking place in the TAL.
Methods
Animal models, biochemical analyses and tissue collection. Kcnj1−/− mice37 and wild-type 
(Kcnj1+/+) littermates were housed in a light- and temperature-controlled environment with ad libitum access to 
tap water and standard chow (Diet AO3, SAFE; 25/18 GR Mucedola Srl, Settimo Milanese, Italy). Urine samples 
were collected using individual metabolic cages (UNO Roestvastaal BV, Zevenaar, The Netherlands) after appro-
priate training. Blood was collected by venous puncture or cardiac puncture at time of sacrifice and centrifuged 
at 2000 g for 15 minutes at 4 °C in heparin-coated tubes (Sarstedt AG, Nürnbrecht, Germany) in order to sepa-
rate plasma from cells. Creatinine, electrolytes and urea were measured on a Synchron CX5 analyser (Beckman 
Coulter, Fullerton, CA, USA), according to the manufacturer’s instructions. Urine and plasma osmolality were 
measured on a multi-sample osmometer (Advanced Instruments Model 2020, Norwood, MA, USA). Urinary 
concentration of uromodulin in mouse urine was assessed by means of a commercial ELISA kit (ab245726, 
Abcam, Cambridge, UK). Following the collection of urine and plasma samples, mice were sacrificed either by 
decapitation or by cervical dislocation following anaesthesia with isoflurane (Minrad International Inc., Orchard 
Park, NY, USA) for the collection of the kidneys. One kidney was immediately homogenized for protein or 
RNA extraction, while the other was further processed for histological analyses. Kcnj1fl/fl mice were generated 
by Ozgene (Perth, Australia) as described elsewhere (Penton et al., MS under revision) and were used to obtain 
kidney tissue for primary mTAL cell culture. Moreover, kidney lysates, frozen tissues and urine samples were 
obtained from tetracycline-inducible kidney-specific Kcnj1 KO mice that had been generated by crossing the 
Kcnj1fl/fl mice with Pax8-rtTA-cre mice24. All of the experiments were performed in accordance with the ethical 
guidelines at University of Zurich (Zurich, Switzerland) and the legislation of animal care and experimentation of 
Canton Zurich, Switzerland. The experimental protocols were approved by the appropriate licensing committee 
(Kanton Zürich Gesundheitsdirektion Veterinäramt; protocol ZH049/17) at the University of Zurich.
Protein samples preparation and immunoblotting. Proteins were extracted from grinded tissue using 
ice-cold RIPA buffer (Sigma-Aldrich, St.-Louis, MO, USA) with the addition of protease and phosphatase inhib-
itors (Roche, Basel, Switzerland), followed by a brief sonication and a centrifugation for 15 min at 1000 g and 
4 °C to remove debris. For the membrane-cytosolic separation, mouse kidneys were solubilized in sucrose buffer 
(1 mM EDTA, 20 mM Imidazole and 250 mM Sucrose, pH 7.2) and pellets enriched in large plasma membranes 
Figure 6. Urinary uromodulin levels in Bartter type 2 patients. (a) Amino acid composition of ROMK, with 
mutations found in Bartter type 2 patients (yellow, missense; red, nonsense). TM: Transmembrane domain. 
(b) Box and whiskers plot of urinary uromodulin (UMOD) levels of Bartter type 2 patients, control relatives 
and a healthy reference population (age ≤ 20, eGFR ≥ 80). Median, 25th and 75th percentiles are indicated on 
the respective plot. (c) Representative Western blot analysis of UMOD in urine samples from Bartter type 2 
patients and control individuals. Samples were loaded according to urinary creatinine. (d) Western blot analysis 
of UMOD in control and deglycosylated (PNGase F treatment) urine samples from Bartter type 2 patients and 
control relatives. Samples were denatured by heating and treated according to the manufacturer’s instructions. 
Full length blot images can be found in Supplementary Figure S2.
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(“membrane fraction”) (16,000 g, 1 h, 4 °C) and in cytoplasmic proteins and cytoplasmic vesicles (“cytosolic frac-
tion”) (200,000 g, 2 h, 4 °C) were sequentially collected. Protein concentrations in kidney/mTAL lysates were 
determined using the bicinchoninic acid (BCA) protein assay kit (Thermo Fischer Scientific, Waltham, MA, 
USA), while urine was loaded according to creatinine concentration. For semi-quantitative Western blot analysis, 
urine samples were denatured by boiling but not reduced. For qualitative Western blot analysis, all urine samples 
were denatured by boiling and reduced using DTT. When indicated, these samples were N-deglycosylated using 
PNGase F (P70404L, New England Biolabs, Ipswich, MA, USA) according to the manufacturer’s instructions. 
Briefly, urine samples were prepared by adding the denaturating buffer and heating for 10 minutes at 100 °C. The 
final reaction was prepared by adding 10% NP-40, G7 Reaction Buffer and PNGase F (H2O for negative controls) 
to the denatured samples, which were then incubated for 1 hour at 37 °C. Kidney samples were thawed on ice, 
normalized for protein levels, diluted in Laemmli sample buffer (Bio-Rad Laboratories Inc., Hercules, CA, USA), 
separated on a 7.5–10% SDS-PAGE gel and blotted onto methanol-activated PVDF membranes. Membranes 
were blocked for 30 min in 5% w/v non-fat dry milk solution at room temperature, followed by overnight incu-
bation at 4 °C with primary antibodies. Thereafter, blots were washed and incubated with peroxidase-conjugated 
secondary antibodies, washed again and visualized by Immun-Star™ enhanced chemiluminescence (Bio-Rad). 
Immunoblots were quantified by densitometry using ImageJ38.
Histological analysis and immunostaining. Kidneys were fixed overnight at 4 °C in 4% formaldehyde 
(Sigma-Aldrich), dehydrated and subsequently embedded in paraffin. Paraffin blocks were cut into 5 µm-thick 
sections, deparaffinized in xylene and re-hydrated in decreasing ethanol concentrations.
Haematoxylin and Eosin (Sigma-Aldrich) staining was performed according to standard protocols and 
the staining was evaluated by use of a Zeiss MIRAX MIDI slide scanner (Carl Zeiss, Oberkochen, Germany). 
Immunostaining was performed on paraffin sections and/or 5 μm thick cryosections obtained from Kcnj1−/− and 
Kcnj1+/+ kidneys. Sections were deparaffinized in xylene and rehydrated using decreasing ethanol concentra-
tions. Heat mediated antigen retrieval was performed using 10 mM citrate buffer (pH 6.0) for 10 min at 98 °C in a 
Histos Pro Rapid Microwave Histoprocessor (Milestone Inc., Shelton, CT). The sections were blocked for 30 min 
in PBS containing 10% normal goat serum (CL1200, Cedarlane Laboratories, Burlington, Canada) at room tem-
perature and incubated with the primary antibody in a humidified chamber for either 2 hours at RT or overnight 
at 4 °C. The sections were then incubated with secondary antibodies in PBS containing 0.5% BSA for 2 hours at 
RT, washed and mounted using Prolong Gold Anti-fade reagent with DAPI (P36931, Thermo Fisher Scientific).
Isolation, culture and treatment of primary mouse TAL cells. Primary cell cultures of mouse TAL 
(mTAL) cells were prepared from wild-type C57/BL6 (Charles River, Suzbach, Germany) mice and Kcnj1fl/fl mice 
as previously described25. Briefly, TALs were isolated under a light microscope on the basis of morphology char-
acteristics and cultured on permeable filter supports (Transwell-COL, pore size 0.4 µm, Corning Costar, USA) 
containing a DMEM:F12-based medium for 7–10 days in a humidified chamber at 37 °C and 5% CO2 until con-
fluent monolayers were formed. For pharmacological inhibition, primary mTAL cultures were treated at the api-
cal side of the filter with 100 µM bumetanide (B3023, Sigma-Aldrich) or 5 mM BaCl2 (342920, Sigma-Aldrich) 
for 12 hours, and 30–60 µM VU591 (SML0077, Sigma-Aldrich) followed by 2 days of serum-free conditions. 
Before and after each experiment the apical medium was collected for further analysis. For expression studies, 
adenovirus constructs used include eGFP under control of a CMV promoter (#1060, Vector Biolabs, Malvern, 
PA, USA) or an individual carrying also Cre-recombinase (#1700, Vector Biolabs). The transduction protocol was 
performed as previously described27. Briefly, the cells were plated onto filters and transduction was performed 
24 h after plating, when cells reached approximately 70–80% of confluence. The cells were subsequently incubated 
for overnight at 37 °C with culture medium containing the virus at the appropriate concentration (0.2125 × 109 
PFU/mL). Culture medium was changed every other day, and the cells were collected for analysis after 5 days. 
Cultures were subjected to transepithelial resistance (Rte) measurements using an EVOM-G potentiometer 
(World Precision Instruments, Sarasota, FL, USA) and Endohm 6 electrodes (WPI). At the end of the experi-
ments, cells were either lysed for RNA/protein collection or fixed for immunofluorescence staining. Thiazolyl 
Blue Tetrazolium Bromide (MTT) assay was performed according to manufacturer instructions. Briefly, cells 
were incubated with 5 mg/mL MTT (Sigma-Aldrich) for 2 hours at 37 °C. MTT formazan crystals were then sol-
ubilised with DMSO and the optical density was measured at 565 nm using an Infinite M Plex microplate reader 
(Tecan, Männedorf, Switzerland).
Immunofluorescence staining of mTAL cells. Confluent monolayers of primary cultured mTAL cells 
were fixed for 20 min on ice with 4% (w/v) formaldehyde (Sigma-Aldrich), quenched for 10 min at room temper-
ature (RT) and permeabilised for 15 min at 37 °C in permeabilisation solution (PS: 0.7% gelatin (#G7041-100G, 
Sigma-Aldrich) and 0.016% saponin (#47036-50GF, Sigma-Aldrich) in H2O). A primary antibody detecting 
uromodulin was diluted in PS and incubated for 1 h at 37 °C. After four washing steps in PS, monolayers were 
incubated for 30 min at 37 °C in PS with a donkey anti-sheep Alexa488 (#A-11015, Thermo Fisher Scientific) sec-
ondary antibody. Next the cells were washed 3-times in PBS containing 0.1% Triton-X (#T9284, Sigma-Aldrich), 
post-fixated for 15 min at RT using 4% formaldehyde in PBS containing DAPI (Life technologies, #D1306), and 
rinsed once with PBS. The filters were cut from the holder and mounted in Prolong Gold Anti-fade reagent 
(Thermo Fisher Scientific). Sections and cells were viewed using a LSM510Meta Confocal microscope (Carl Zeiss, 
Oberkochen, Germany), with an ×63/1.4 Plan- Apochromat oil-immersion objective; x40/NA 1.25 oil immersion 
objective and an x20/ NA 0.7 multi immersion objective.
RNA isolation, reverse transcription and quantitative PCR. Analysis of gene expression levels in 
mouse kidneys and mTAL cells were performed based on the MIQUE guidelines39. In brief, the extraction of 
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total RNA from mTAL cells was performed using RNAqueous-Micro kit (Ambion, Huntingdon, UK). Total RNA 
was extracted from kidney using Aurum TM Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad, Hercules, CA), 
following the protocol of the manufacturer. Contamination by genomic DNA was eliminated by DNase I treat-
ment. Reverse transcriptase reaction with iScript TM cDNA Synthesis Kit (Bio Rad) was executed with up to 1 µg 
of RNA. When needed, PCR products were sizefractionated on 1.5% agarose gel and stained with EZ-VisionR 
One (AMRESCO, Solon, OH). The variations in mRNA levels of the target genes were established by relative 
RT-qPCR with a CFX96TM Real-Time PCR Detection System and the iQ™ SYBR Green Supermix (Bio-Rad) for 
the detection of single PCR product accumulation. 100 nM of sense and anti-sense primers were used in a final 
volume of 20 µl in iQ™ SYBR Green Supermix (Bio-Rad) to perform RT-qPCR analyses (in duplicate). Primers 
specific to targets were designed with Beacon Design 2.0 (Premier Biosoft International, Palo Alto, CA). PCR 
conditions were: 95 °C, 3 min followed by 40 cycles of 15 sec, 95 °C and 30 seconds at 60 °C. The efficiency of each 
set of primers was determined by dilution curves (Suppl. Table S3). For TAL cell expression studies, Gapdh was 
used as a reference gene. GeNorm version 3.4 was used to characterize the expression stability of the candidate 
reference genes in kidney. Normalization factor was determined using 6 housekeeping genes (18 S, 36B4, Actb, 
Gapdh, Hprt1, Ppia)40. The relative changes were determined by the formula: 2−ΔΔct and expressed as percentage 
relative to wild-type.
Urinary uromodulin measurements. Patients with established diagnosis of antenatal Bartter syndrome 
type 2 and age- and gender-matched relatives were recruited (Suppl. Table S1). The reference samples were 
obtained from participants of the population-based, Swiss Kidney Project on Genes in Hypertension (SKIPOGH) 
study, and matched for age and eGFR41. Recruitment procedures have been previously described41,42. All patients 
and controls gave informed consent. The experimental protocols were approved by the Ethics Committee of the 
Universities of Bern, Geneva, and Lausanne (Switzerland); the University of Louvain (Brussels, Belgium); and the 
EURenOmics consortium (FP7, 2007–2013, grant agreement no. 305608). All experiments were performed in 
accordance with relevant guidelines and regulations.
Urinary uromodulin concentration was measured using a well-established ELISA based on a sheep 
anti-human uromodulin antibody as the capture antibody, a mouse monoclonal anti-human uromodulin detec-
tion antibody, and a goat anti-mouse IgG horseradish peroxidase–conjugated protein (#172-1011, Bio-Rad) as a 
secondary antibody28. For detection, a 250 µg/L O-Phenylenediamine dihydrochloride (OPD) substrate solution 
was freshly prepared in phosphate-citrate buffer (0.1 M citric acid monohydrate, 0.2 M Na2HPO4, 0.006 M H2O2, 
pH 5.5). Human uromodulin (Millipore, Billerica, MA, USA) was used to establish the standard curve. The ELISA 
assay has a sensitivity of 2.8 ng/ml and a linearity of 1.028. Urinary creatinine levels were measured using Beckman 
Coulter Synchron® System Creatinine Assay (Unicell DxC Synchron® clinical System), according to manufac-
turer instructions. Uromodulin was indexed to creatinine to correct for variations in urine concentration.
Antibodies. The following primary antibodies were used: sheep anti-uromodulin (K90071C, Meridian 
Life Science Inc., Cincinnati, OH, USA; 1:500 for WB and 1:300 for IF), mouse anti-uromodulin (CL 1032 A; 
Cedarlane Laboratories; for ELISA), mouse anti-flotillin-1 (BD 610821, BD Biosciences, Franklin Lakes, NJ, 1:500 
for WB), rabbit anti-GAPDH (2118, Cell Signaling Technology, Danvers, MA, USA; 1:500 for WB), mouse anti-β 
actin (A5441, Sigma-Aldrich; 1:10 000 for WB, rabbit anti-NKCC2 (AB3562P, Merck-Millipore, Burlington, MA, 
USA; 1:500 for WB and 1:100 for IF), rabbit anti-ROMK (Penton et al., MS under revision; 1:1000 for WB and 
1:5000 for IF).
Statistical analysis. All values are expressed as mean ± SEM. Comparisons between groups were per-
formed using Student’s t-test or one-way ANOVA in case of 3 or more groups’ comparisons. In the latter case, 
Tukey-Kramer’s post hoc analysis was also performed. P values ≤ 0.05 were considered statistically significant.
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